Publicacions en col·laboració amb investigadors/es de Hospital Vall d'Hebron (3)

2023

  1. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

    Journal of medical economics, Vol. 26, Núm. 1, pp. 445-453

  2. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

    BMC Pulmonary Medicine, Vol. 23, Núm. 1

2015

  1. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: Variation between label dosage and real-world use

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 5, pp. 851-858